SciCombinator

Discover the most talked about and latest scientific content & concepts.

S Chumsri, J Weidler, S Ali, S Balasubramanian, G Wallweber, L DeFazio-Eli, A Chenna, W Huang, A DeRidder, L Goicocheal and EA Perez
Abstract
In the current genomic era, increasing evidence demonstrates that approximately 2% of HER2-negative breast cancers, by current standard testings, harbor activating mutations of ERBB2. However, whether patients with HER2-negative breast cancer with activating mutations of ERBB2 also experience response to anti-HER2 therapies remains unclear. This case report describes a patient with HER2-nonamplified heavily pretreated breast cancer who experienced prolonged response to trastuzumab in combination with pertuzumab and fulvestrant. Further molecular analysis demonstrated that her tumors had an elevated HER2 dimerization that corresponded to ERBB2 S310F mutation. Located in the extracellular domain of the HER2 protein, this mutation was reported to promote noncovalent dimerization that results in the activation of the downstream signaling pathways. This case highlights the fact that HER2-targeted therapy may be valuable in patients harboring an ERBB2 S310F mutation.
Tweets*
0
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
1
Concepts
Tamoxifen, HER2/neu, Trastuzumab, Cancer, Breast cancer
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com